It’s difficult to the describe 4chan—the anonymous Web imageboard that is known equally for its ability to generate memes and a sense of disgust with the uninitiated—without using some variation on the the words “notorious” or “dark corner of Web”. Which is perhaps why DrawQuest—the new iPad app developed by 4chan founder Chris Poole (better known as “moot” in the land of ones and zeroes) is so surprising: It’s as PG as it is addictive. …read more
Source: FULL ARTICLE at Forbes Latest
By Reuters
Filed under: Company News, Earnings, Consumer Goods, Manufacturing, Stocks
Kimberly-Clark posted a bigger-than-expected jump in first-quarter earnings and raised its forecast for the year Friday as the maker of Kleenex tissues and Huggies diapers saw strong growth in its international markets and cut costs.
The company, which competes against larger rival Procter & Gamble Co. (PG) in categories such as diapers and paper products, said it cut $85 million in costs during the quarter.
Shares of the company rose 2.6 percent to $104 in trading before the market opened.
Excluding items such as restructuring costs, Kimberly-Clark earned $1.48 a share, well ahead of an average forecast by analysts of $1.34, according to Thomson Reuters I/B/E/S.
Net income rose to $531 million, or $1.36 a share, from $468 million, or $1.18 a share, a year earlier.
Sales rose 1.5 percent to $5.32 billion, topping analysts’ forecast of $5.28 billion.
In personal care, the company’s largest segment with products such as Huggies diapers, North American sales were flat as a 1 percent price increase offset lower sales volumes. Sales of these products rose 4 percent in international markets, helped by a 2 percent price increase and growth in countries such as China, Russia and South Korea.
Kimberly-Clark Corp. (KMB) said it expected to post 2013 earnings a share of $5.60 to $5.75, excluding items, versus its prior target of $5.50 to $5.65. The analysts’ average forecast is $5.59.
While the company has been cutting some expenses, materials and distribution costs rose in the quarter. Input costs were up $35 million from a year earlier, with increases of $15 million for fiber, $10 million for other raw materials and $10 million for distribution, it said.
Permalink | Email this | Linking Blogs | Comments
From: http://www.dailyfinance.com/2013/04/19/kimberly-clark-earnings/
Filed under: Investing
The role of central banks in stimulus will be considered at International Monetary Fund (IMF) and G-20 gatherings. (Reuters)
Display ad revenue at Yahoo! (NASDAQ: YHOO) drops sharply. (Reuters)
News Corp. (NASDAQ: NWSA) will call its entertainment company 21st Century Fox. (Reuters)
Carl Icahn agrees to limit his stake in Dell Inc. (NASDAQ: DELL) but can join other bidders to make an offer for the company. (Reuters)
Procter & Gamble Co. (NYSE: PG) will lengthen the number of days after which it pays suppliers, which will allow it access to $2 billion in cash. (WSJ)
A new IMF report attacks the results of austerity taken on by financially troubled nations. (WSJ)
A reservations system glitch limits American Airlines bookings and causes a number of flights to be halted. (WSJ)
Boeing Co. (NYSE: BA) completes tests of batteries on its Dreamliner 787, but the FAA has not approved them. (WSJ)
Intel Corp.’s (NASDAQ: INTC) profits drop by 25% as PC sales tumble. (WSJ)
Investment manager John Paulson loses $1.5 billion in his bet on gold prices. (FT)
The drop in gold prices hits central bank asset values by $560 billion. (Bloomberg)
Filed under: 24/7 Wall St. Wire, Press Digest Tagged: BA, DELL, INTC, NWSA, PG, YHOO
Read | Permalink | Email this | Linking Blogs | Comments
From: http://www.dailyfinance.com/2013/04/17/media-digest-4172013-reuters-wsj-ft-bloomberg/
Flight diverted after family raises concerns over PG-13 inflight movie...
(First column, 22nd story, link)
Source: Drudge Report
Did you know Dwayne “The Rock” Johnson is making a Hercules movie with Brett Ratner? Because he’s not too busy reviving franchises and wrestling and palling around with Navy SEALs…
Anyway, now the myth-based picture has gained a couple of actors who have surely been touched by the gods: Ian McShane and John Hurt. In perhaps less godly news, Aksel Hennie, Rufus Sewell, Joseph Fiennes and Rebecca Ferguson have also been recently cast in the film, which is said to be “taking a more grounded approach to the classic Greek hero and ditches the supernatural. Hercules is portrayed not as the son of Zeus but rather as a mortal with a fearsome reputation. He leads a team of mercenaries on a job where all is ominously not what it appears.” I wonder if he’ll still kill his children in a fit of madness though? Does that work for a PG-13?
…read more
Source: FULL ARTICLE at IGN Movies
By Business Wirevia The Motley Fool
Filed under: Investing
Regal Entertainment Group Announces Summer Movie Express 2013
Spring into summer with selected movies only $1 at nearly 300 locations
KNOXVILLE, Tenn.–(BUSINESS WIRE)– Regal Entertainment Group (NYS: RGC) , a leading motion picture exhibitor owning and operating the largest theatre circuit in the United States, today announced the launch of the Regal Summer Movie Express for 2013. During this 9-week festival, 296 Regal Cinemas, United Artists and Edwards Theatres will offer selected G or PG rated movies for only a dollar at 10:00 on Tuesday and Wednesday mornings.
“We are excited to invite moviegoers to climb back aboard the Regal Summer Movie Express. This year Regal will feature a fantastic selection of films including Parental Guidance and Dr. Seuss’ The Lorax,” stated Russ Nunley, Vice President of Marketing and Communications for Regal Entertainment Group. “Regal is proud to provide this great activity each summer for moviegoers of all ages.”
Since 1991, Regal has hosted special summertime entertainment for families to enjoy and to foster a love of moviegoing in each new generation. Participating locations and their start dates are listed online at: http://www.regmovies.com/Movies/Summer-Movie-Express
About Regal Entertainment Group:
Regal Entertainment Group (NYS: RGC) operates the largest and most geographically diverse theatre circuit in the United States, consisting of 6,862 screens in 538 locations in 38 states and the District of Columbia as of February 21, 2013. The Company operates theatres in 43 of the top 50 U.S. designated market areas. We believe that the size, reach and quality of the Company’s theatre circuit not only provide its patrons with a convenient and enjoyable movie-going experience, but is also an exceptional platform to realize economies of scale in theatre operations. Additional information is available on the Company’s Web site at www.REGmovies.com.
Tweet This: Can’t wait for all of the $1 films @RegalMovies Summer Movie Express! Theatres and dates announced: REGmovi.es/13cD6dd
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130321006280/en/
Media Contact:
Russ Nunley
Vice President of Marketing & Communications
Regal Entertainment …read more
Source: FULL ARTICLE at DailyFinance
By Business Wirevia The Motley Fool
Filed under: Investing
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled ® Melphalan
HENDERSON, Nev.–(BUSINESS WIRE)– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has gained global development and commercialization rights to Ligand Pharmaceuticals’ (NAS: LGND) Captisol-enabled®, propylene glycol-free (PG-free) melphalan. Captisol-enabled melphalan is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma.
Spectrum is assuming the responsibility for the ongoing pivotal clinical trial and will be responsible for filing an NDA, which is anticipated in the first half of 2014. Under the license agreement, Ligand will receive a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization.
“We are pleased to add this late-stage program to our portfolio, which includes belinostat, for which we anticipate an NDA filing mid-year, and apaziquone, for which we expect to file an NDA in 2014,” stated Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. “Captisol-enabled melphalan is designed to meet the need for a formulation of melphalan that is free of propylene glycol, which has been associated with renal and cardiac side effects. The Captisol technology may allow longer duration of administration and slower infusion rates, potentially enabling a higher dose intensity of pre-transplant chemotherapy to optimize efficacy. We look …read more
Source: FULL ARTICLE at DailyFinance
By Business Wirevia The Motley Fool
Filed under: Investing
Ligand Signs Global License Agreement with Spectrum Pharmaceuticals for Captisol-Enabled ® Melphalan
Ligand to Receive License Fee, Eligible for Milestones and Royalties
Raises Full Year Revenue and Earnings Guidance and Provides First Quarter Forecast
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces the signing of global license and supply agreements with Spectrum Pharmaceuticals, Inc. (NAS: SPPI) for the development and commercialization of Ligand’s Captisol-enabled®, propylene glycol-free (PG-free) melphalan. Under the terms of the license agreement, Ligand is entitled to receive a license fee and is eligible to receive more than $50 million in potential milestone payments. Ligand is also eligible to receive royalties on future net sales of Captisol-enabled melphalan. Further details regarding the transaction are provided in Ligand’s Form 8-K that is being filed today.
The Captisol-enabled melphalan program is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum will immediately assume all development of the program as a result of this license.
“We are pleased to have forged this agreement,” commented John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. “Spectrum has an established oncology and hematology business, and this melphalan product is an ideal complement to their two commercial hematology products, Zevalin and Folotyn, including an expected high degree of commercial call overlap. Spectrum’s highly experienced, oncology-focused R&D team is committed to the efficient development of Captisol-enabled melphalan, and has established relationships with key investigators.”
Full Year 2013 Revenue and Earnings Guidance and First Quarter Forecast
Ligand now expects 2013 total revenues to be in the range of $43 million to $46 million, versus previous guidance of $41 million to $44 million. Earnings per share for 2013 are expected to be in the range of $0.47 to $0.51, versus previous guidance of $0.35 to $0.39. Ligand estimates revenue for the first quarter of 2013 to be in the range of $10 million to $11 million, with first quarter earnings per share in the range of $0.10 to $0.13. Earnings per share guidance does not include the effects of any increase or decrease in contingent liabilities.
About Captisol-enabled Melphalan
…read more
Source: FULL ARTICLE at DailyFinance
By MarketNewsVideo Proctor & Gamble (PG) had its earnings estimates lowered by JPMorgan (JPM) as while the firm believes that performance will increase during the future, the organic top line is stagnant. …read more
Source: FULL ARTICLE at Forbes Markets
By GuruFocus, Contributor This is the latest stock picks from Bill & Melinda Gates Foundation Trust. The foundation’s portfolio is run by Michael Larson. If you look at the portfolio, it is a lot like the holdings of Warren Buffett. It is filled with a list of large cap high quality companies. …read more
Source: FULL ARTICLE at Forbes Latest
As expected, Man of Steel will soar into theaters with a PG-13 rating.
According to Rope of Silicon, the Motion Picture Association of America (MPAA) gave Man of Steel a PG-13 rating “for intense sequences of sci-fi violence, action and destruction, and for some language.”
Man of Steel opens June 14.
Source: FULL ARTICLE at IGN Movies
By Neal Colgrass 
Source: FULL ARTICLE at Newser – Home
John McClane’s last outing, Live Free or Die Hard, may have been rated PG-13, but a TV spot confirms his next adventure, A Good Day to Die Hard, will be rated R.
Source: FULL ARTICLE at IGN Movies Videos
John McClane’s last outing, Live Free or Die Hard, may have been rated PG-13, but sources tell IGN that it appears his next adventure, A Good Day to Die Hard, will be rated R.
All the other Die Hard films with the exception of the fourth entry have been rated R.
A Good Day to Die Hard opens February 14.
Source: FULL ARTICLE at IGN Movies
By MarketNewsVideo Procter & Gamble (PG) maintained its quarterly dividend of 56.2 cents per share. The disbursement will be made on or after February 15 to shareholders of record on January 18.
Source: FULL ARTICLE at Forbes Markets
By Zach Bowman
Filed under: Marketing/Advertising, Toyota, Celebrities
Toyota has turned to actress Kaley Cuoco for a little help during this year’s Super Bowl. The Big Bang Theory star will play a role front and center in the automaker’s spot for the game, and Toyota fans have a chance to show up in the ad as well. Anyone can take a photo and upload it via Twitter or Instagram with the hashtag #wishgranted for a chance to have their image featured in the commercial on February 3. While Toyota isn’t saying exactly what the pictures will be used for, we imagine the photos will need to be rated PG. Sorry, guys.
Toyota isn’t saying much more about the ad or what its plot line will offer, at least for now. Expect to hear more details surface as we get closer to game day. In the interim, you can check out the brief press release below for more information, or check out Toyota’s “Get In The Big Game” web page at the link below.
Continue reading Toyota Super Bowl ad to star Big Bang Theory bombshell Kaley Cuoco
Toyota Super Bowl ad to star Big Bang Theory bombshell Kaley Cuoco originally appeared on Autoblog on Tue, 08 Jan 2013 14:30:00 EST. Please see our terms for use of feeds.
Permalink | Email this | Comments
Source: FULL ARTICLE at Autoblog
By ETFChannel.comLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (AMEX: VTV) where we have detected an approximate $105.9 million dollar inflow — that’s a 1.5% increase week over week in outstanding units (from 117,034,485 to 118,834,485). Among the largest underlying components of VTV, in trading today Chevron Corporation (NYSE: CVX) is up about 0.2%, Procter & Gamble Co. (NYSE: PG) is off about 0.6%, and Wells Fargo & Co. (NYSE: WFC) is higher by about 0.1%. For a complete list of holdings, visit the VTV Holdings page »
Source: Forbes Markets
